RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer

PURPOSE: While chemotherapy remains the standard treatment for triple-negative breast cancer (TNBC), identifying and managing chemoresistant tumors has proven elusive. We sought to discover hallmarks and therapeutically actionable features of refractory TNBC through molecular analysis of primary che...

Descripción completa

Detalles Bibliográficos
Autores principales: Koh, Siang-Boon, Ross, Kenneth, Isakoff, Steven J., Melkonjan, Nsan, He, Lei, Matissek, Karina J., Schultz, Andrew, Mayer, Erica L., Traina, Tiffany A., Carey, Lisa A., Rugo, Hope S., Liu, Minetta C., Stearns, Vered, Langenbucher, Adam, Saladi, Srinivas Vinod, Ramaswamy, Sridhar, Lawrence, Michael S., Ellisen, Leif W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Translational Cancer Mechanisms and Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8416935/
https://www.ncbi.nlm.nih.gov/pubmed/34168046
http://dx.doi.org/10.1158/1078-0432.CCR-21-0714

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8416935/
https://www.ncbi.nlm.nih.gov/pubmed/34168046
http://dx.doi.org/10.1158/1078-0432.CCR-21-0714

Ejemplares similares